SI-BONE, Inc. (NASDAQ:SIBN) Shares Purchased by AQR Capital Management LLC

AQR Capital Management LLC lifted its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 54.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 31,864 shares of the company’s stock after acquiring an additional 11,270 shares during the period. AQR Capital Management LLC owned 0.08% of SI-BONE worth $412,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of SIBN. Canada Pension Plan Investment Board acquired a new position in shares of SI-BONE during the second quarter valued at approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after acquiring an additional 2,108 shares during the last quarter. Arizona State Retirement System lifted its position in shares of SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after acquiring an additional 903 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of SI-BONE during the 2nd quarter worth $152,000. Finally, RiverPark Advisors LLC grew its holdings in shares of SI-BONE by 260.4% in the 1st quarter. RiverPark Advisors LLC now owns 11,357 shares of the company’s stock worth $186,000 after acquiring an additional 8,206 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Needham & Company LLC dropped their target price on SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Morgan Stanley decreased their target price on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Truist Financial cut their price objective on SI-BONE from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $22.67.

Insider Transactions at SI-BONE

In related news, insider Anthony J. Recupero sold 3,305 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total value of $44,881.90. Following the completion of the transaction, the insider now directly owns 233,412 shares in the company, valued at approximately $3,169,734.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Anthony J. Recupero sold 3,305 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the completion of the transaction, the insider now directly owns 233,412 shares of the company’s stock, valued at approximately $3,169,734.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura Francis sold 9,967 shares of SI-BONE stock in a transaction on Friday, August 16th. The shares were sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the sale, the chief executive officer now owns 492,923 shares in the company, valued at approximately $6,822,054.32. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 25,019 shares of company stock worth $349,879 in the last 90 days. Insiders own 3.90% of the company’s stock.

SI-BONE Stock Performance

NASDAQ SIBN opened at $13.14 on Wednesday. SI-BONE, Inc. has a 12-month low of $11.76 and a 12-month high of $21.70. The firm has a 50-day moving average price of $14.73 and a two-hundred day moving average price of $14.55. The company has a market capitalization of $547.81 million, a P/E ratio of -13.01 and a beta of 1.22. The company has a quick ratio of 8.12, a current ratio of 9.17 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The firm had revenue of $39.97 million during the quarter, compared to the consensus estimate of $38.95 million. During the same period last year, the company earned ($0.30) earnings per share. Analysts anticipate that SI-BONE, Inc. will post -0.89 earnings per share for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.